A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.
about
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesEvolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative NeoplasmsNew ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromeThe evolving treatment paradigm in myelofibrosisNovel therapies for myelofibrosisPractical management of patients with myelofibrosis receiving ruxolitinib.Zebularine suppresses TGF-beta-induced lens epithelial cell-myofibroblast transdifferentiation by inhibiting MeCP2.Effects of a novel DNA methyltransferase inhibitor Zebularine on human lens epithelial cells.Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues.Epigenetic mechanisms regulating normal and malignant haematopoiesis: new therapeutic targets for clinical medicine.Deactylase inhibition in myeloproliferative neoplasms.Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitorsDefinition and management of ruxolitinib treatment failure in myelofibrosis.Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?Emerging drugs for the treatment of myelofibrosis.JAK2 inhibitors for myeloproliferative neoplasms: what is next?Pharmacologic management of myelofibrosis.Myelofibrosis: an update on drug therapy in 2016.Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine.Management of myelofibrosis: JAK inhibition and beyond.Treatment of Myelofibrosis: Old and New Strategies.Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms.Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms.JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms.Novel Therapies for Myelofibrosis.Pharmacotherapy of Myelofibrosis.Targeting the epigenome for treatment of cancer.
P2860
Q26752940-6C5A67F3-AFD4-46FE-98B9-EA8674061038Q26766319-4AC0D25C-5733-42AF-93BF-5A1F045CFB86Q26829132-0B215B3F-A554-431E-AA32-7839A3E0848BQ27021968-6BB069DC-94E9-4795-8FA1-CDE39A086D65Q28081693-D1163D1E-AA83-4212-8C86-BF3D1A84C62BQ33410649-DF60B076-507B-4224-8D03-437790A85B13Q35531772-C6082BBE-6785-40F8-8061-167BD02BC647Q35673407-99314C78-1351-4D45-A8A9-C0475E3B6DECQ35988523-338E8F09-34FA-488B-8085-97E40C62A659Q36001930-98B9B84D-7450-4135-875B-12FCACBBC1FAQ36782943-01607DEE-E13C-48D2-9BCA-62BB80430862Q37310619-85265737-CAB6-4F2E-8CAD-DC6D3B792760Q37529843-82A802A4-F991-45AC-A613-F42458B35CF6Q37566249-1DF27482-B9FE-46C8-A4FD-13C7241E7E74Q37691486-69BC73F4-0285-4EB1-90E9-B9E7C0175480Q37815421-C4070CB1-4A52-4872-A9A8-DDAF81E3C7BEQ38031262-82BBCF28-3EEF-47A3-8035-AED5B3470EF6Q38287012-6B141E90-73B3-4DEE-93F2-30DF9BCCFB61Q38349213-79366CAB-30F4-4657-9433-8F2DD664E7FDQ38543775-7CF4625F-4A9F-4F46-AE54-436614346792Q38684435-55C08654-B5DF-4E68-A0A6-FEDF3F019084Q38965408-8EC91E30-24D1-4143-8A4C-2D075523CCD0Q38989215-31DC4495-3839-4EDF-A2EE-FF410ED1D58AQ39202346-1F9FB343-244C-4271-A820-2E5606DDF757Q39232415-472D8DAE-1659-4F5B-9A11-5D3F57AE642BQ39349869-79BFB213-4BC5-4A0A-A39F-9296A5C2C288Q41084893-A37AB759-5836-4392-AECA-B47262EFE75AQ42278621-537A205F-7959-4350-A8DB-C96DA6BCE0DAQ42720284-12786C1D-D64A-4A75-8774-3344CFD4A281Q46110570-FCB626D0-28D3-44C1-AA98-57BC301114B5Q48109284-ADD0B226-8C6D-48CB-96CC-7342FFCEC3A0Q48309941-C3449EE4-77BD-4705-8BC1-EE431519EF72Q52665839-D15E6AF7-3C92-40B5-8E12-5AED18BFB7D0Q52817185-E69BADA9-34F0-4ABA-9017-BAB8BEDB33EEQ53119304-711912A4-5E2D-4A89-A160-A0E508A3D0D5Q53201323-B9FF6FFF-F3C0-49D4-B903-09B88F32334B
P2860
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
A phase II study of 5-azacitid ...... lycythemia vera myelofibrosis.
@ast
A phase II study of 5-azacitid ...... lycythemia vera myelofibrosis.
@en
type
label
A phase II study of 5-azacitid ...... lycythemia vera myelofibrosis.
@ast
A phase II study of 5-azacitid ...... lycythemia vera myelofibrosis.
@en
prefLabel
A phase II study of 5-azacitid ...... lycythemia vera myelofibrosis.
@ast
A phase II study of 5-azacitid ...... lycythemia vera myelofibrosis.
@en
P2093
P2860
P356
P1433
P1476
A phase II study of 5-azacitid ...... olycythemia vera myelofibrosis
@en
P2093
A Quintás-Cardama
G Garcia-Manero
H Kantarjian
J E Cortes
S Kornblau
T Manshouri
P2860
P2888
P304
P356
10.1038/LEU.2008.91
P577
2008-04-03T00:00:00Z